OncoMatch/Clinical Trials/NCT06999187
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Is NCT06999187 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies DR-0202 for triple negative breast cancer.
Treatment: DR-0202 — A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Cervical Cancer
Prostate Cancer
Pancreatic Cancer
Endometrial Cancer
Ovarian Cancer
Gastric Cancer
Esophageal Carcinoma
Urothelial Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
adequate marrow reserve
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dren Investigational Site · Denver, Colorado
- Dren Investigational Site · Orlando, Florida
- Dren Investigational Site · Sarasota, Florida
- Dren Investigational Site · Huntersville, North Carolina
- Dren Investigational Site · Oklahoma City, Oklahoma
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06999187 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify